|

Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic Implications

RECRUITINGN/ASponsored by European Institute of Oncology
Actively Recruiting
PhaseN/A
SponsorEuropean Institute of Oncology
Started2019-10-09
Est. completion2024-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06321692

Summary

This study is for patients with neuroendocrine tumours (NET) with or without carcinoid syndrome followed by NET Unit of European Institute of Oncology. The objective of the trial is to evaluate biochemical markers of myocardial injury (high-sensitive troponins), haemodyinamic markers (pro-brain natriuretic peptide (BNP), N-terminal (NT)-BNP (NT-proBNP)), and markers of fibrosis (Suppression of Tumorigenicity 2 (ST2) in patients with neuroendocrine tumours (NET) with or without carcinoid syndrome.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* patients diagnosed with metastatic NET with or without carcinoid referred to the Unit of Neuroendocrine Tumors of European Institute of Oncology

Exclusion Criteria:

* age \<18 years
* patients diagnosed with heart disease prior to diagnosis of NET

Conditions2

CancerNeuroendocrine Tumors

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.